• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: PENUMBRA, INC. PENUMBRA SYSTEM RED 62 REPERFUSION CATHETER; NRY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

PENUMBRA, INC. PENUMBRA SYSTEM RED 62 REPERFUSION CATHETER; NRY Back to Search Results
Catalog Number RED62SKIT
Medical Device Problem Code Fracture (1260)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 07/18/2023
Type of Reportable Event Malfunction
Event or Problem Description
The patient was undergoing a thrombectomy procedure in the m2 segment of the middle cerebral artery (mca) using a penumbra system red 62 reperfusion catheter (red62), a velocity delivery microcatheter (velocity), a benchmark bmx96 access system (bmx96), a stent retriever and a guidewire.During the procedure, the physician advanced the stent retriever using the velocity and the red62 to the target location.The physician then removed the guidewire and the velocity and trapped the clot inside the stent retriever.It was reported that the physician corked the stent retriever outside the red62 and then removed the stent retriever and the red62 together.Upon removal, the distal end of the red62 was noticed to be fractured but remained connected.The procedure was completed at this point and thrombolysis in cerebral infarction (tici) grade 3 was achieved.There was no report of an adverse effect to the patient.
 
Additional Manufacturer Narrative
Evaluation of the returned red62 confirmed that the device was fractured.Evaluation also revealed that a non-penumbra stent retriever was retracted into the red62.If the stent retriever and red62 are forcefully manipulated against resistance during retraction, damage such as a fracture may occur.Penumbra products are visually inspected during in-process inspection and during quality inspection after manufacturing.The manufacturing records for this lot were reviewed and did not reveal any outstanding discrepancies, design, or quality concerns.H3 other text : placeholder.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PENUMBRA SYSTEM RED 62 REPERFUSION CATHETER
Common Device Name
NRY
Manufacturer (Section D)
PENUMBRA, INC.
one penumbra place
alameda CA 94502
Manufacturer Contact
veronica farris
one penumbra place
alameda, CA 94502
5107483200
MDR Report Key17514430
Report Number3005168196-2023-00386
Device Sequence Number5576280
Product Code NRY
UDI-Device Identifier00815948023536
UDI-Public815948023536
Combination Product (Y/N)N
Initial Reporter StateNJ
Initial Reporter CountryUS
PMA/510(K) Number
K203440
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source Health Professional,Company Representative
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 08/11/2023
Report Date (Section F) 01/01/2005
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date05/02/2025
Device Catalogue NumberRED62SKIT
Device Lot NumberF00000427
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer07/20/2023
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? Yes
Date Report to Manufacturer01/10/2005
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 07/18/2023
Initial Report FDA Received Date08/11/2023
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured05/03/2022
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient Age68 YR
Patient SexFemale
Date Report Sent to FDA01/01/2005
-
-